Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04664101
Other study ID # Pro00105798
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 2, 2022
Est. completion date December 1, 2023

Study information

Verified date January 2024
Source Duke University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

REmotely Monitored, Mobile Health-Supported High Intensity Interval Training after COVID-19 critical illness (REMM-HIIT-COVID-19)


Description:

REmotely Monitored, Mhealth (REMM) supported High Intensity Interval Training (HIIT to improve recovery after Intensive Care Unit (ICU) discharge in patients with COVID-19 (REMM-HIIT-ICU-COVID) will evaluate the feasibility of clinical-, physiological- and patient-centered outcomes associated with a remotely monitored, Mhealth-supported high intensity interval rehabilitation exercise training to improve the functional recovery of survivors who have experienced critical illness with COVID-19 and have been discharged home from the hospital.


Recruitment information / eligibility

Status Completed
Enrollment 13
Est. completion date December 1, 2023
Est. primary completion date August 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age >= 18 years 2. ICU admission and subsequent discharge for primary diagnosis of COVID-19 respiratory failure or infection requiring intubation and mechanical ventilation for > 48 hours with an ICU length of stay of = 4 days. 3. Ability to ambulate with or without a gait aid prior to hospital discharge 4. Expected hospital discharge directly back to patient's residence (not to a skilled nursing facility, inpatient rehabilitation center, or long-term acute care hospital) Exclusion Criteria: 1. Not ambulating independently prior to COVID-19 illness (use of a gait aid permitted) 2. Functional impairment resulting in inability to exercise at hospital discharge (including need for home oxygen requirement) 3. Unable or unwilling to follow coaching via mobile-health iPhone interaction 4. Any absolute contraindications to exercise (as outlined in the American Thoracic Society Guidelines for Cardiopulmonary Exercise Testing), including but not limited to: 1. Recent (< 5 days) acute primary cardiac event 2. Unstable Angina 3. Uncontrolled dysrhythmias causing symptoms or hemodynamic compromise 4. Symptomatic aortic stenosis 5. Uncontrolled symptomatic heart failure 6. Acute myocarditis or pericarditis 7. Suspected or known dissecting aneurysm

Study Design


Intervention

Behavioral:
REmotely Monitored, Mhealth (REMM) supported High Intensity Interval Training (HIIT)
REmotely Monitored, Mhealth (REMM) supported High Intensity Interval Training (HIIT) The intervention consists of high intensity interval training, consisting of a 30-minute exercise session that includes 10 x 1-minute intervals of high intensity 3x/week (e.g., Monday, Wednesday, Friday) and supplemented with 2 sessions per week of strength, balance, and mobility exercises (e.g., Tuesday, Thursday). Exercise will be supported by an activity tracker, which will allow study personnel to track patient heart rates during exercise on a daily basis, allowing them to provide individualized feedback and coaching.
Other:
Comparator
Patients randomized to the control arm will receive the same technology platform and education on exercise options, including HIIT, but will return home to exercise as they see fit without personalized instruction and coaching. They will be remotely monitored, but will not receive feedback unless any adverse events are noted

Locations

Country Name City State
United States Duke University Medical Center Durham North Carolina
United States Vanderbilt University Nashville Tennessee

Sponsors (2)

Lead Sponsor Collaborator
Duke University Vanderbilt University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in biomarkers of aging and resilience, and mitochondrial function from baseline to 3 months post-discharge Measured by peripheral blood mononuclear cell (PBMC) Hospital discharge (baseline), 3 months post-discharge
Other Change in biomarkers of aging and resilience, and mitochondrial function from baseline to 3 months post-discharge Measured by plasma Hospital discharge (baseline), 3 months post-discharge
Primary Peak oxygen consumption (V02P) at 3 months after hospital discharge 3 months post-discharge
Secondary Change in 6 minute walk test distance from baseline to 3 months after hospital discharge distance walked in 6 minutes Hospital discharge (baseline), 3 months post-discharge
Secondary Change in muscle mass from baseline to 3 months after hospital discharge Measured by muscle sound Hospital discharge (baseline), 3 months post-discharge
Secondary Change in muscle strength from baseline to 3 months after hospital discharge Measured by Fried Frailty (includes Hand Grip strength) Hospital discharge (baseline), 3 months post-discharge
Secondary Change in muscle strength from baseline to 3 months after hospital discharge Measured by quadriceps strength (Quadricep muscle dynamometry) Hospital discharge (baseline), 3 months post-discharge
Secondary Cognition at 3 months after hospital discharge Measured by Repeatable Battery for Assessment of Neuropsychological Status (RBANS) 3 months post-discharge
Secondary Change in cognition from baseline to 3 months after hospital discharge. Measured by Montreal Cognitive Assessment (MOCA) Hospital discharge (baseline), 3 months post-discharge
Secondary Change in cognition from baseline to 3 months after hospital discharge. Measured by Hayling Sentence Completion Hospital discharge (baseline), 3 months post-discharge
Secondary Change in cognition from baseline to 3 months after hospital discharge. Measured by PROMIS Cognitive function Hospital discharge (baseline), 3 months post-discharge
Secondary Change in cognition from 3 months to 6 months after hospital discharge. Measured by PROMIS Cognitive function 3 months post-discharge, 6 months post-hospital discharge
Secondary Change in quality of life from baseline to 3 months after hospital discharge. Measured by Sociodemographic survey Hospital discharge (baseline), 3 months post-discharge
Secondary Change in quality of life from baseline to 3 months after hospital discharge. Measured by Employment Survey Hospital discharge (baseline), 3 months post-discharge
Secondary Change in quality of life from baseline to 3 months after hospital discharge. Measured by EQ-5D-5L Hospital discharge (baseline), 3 months post-discharge
Secondary Change in quality of life from baseline to 3 months after hospital discharge. Measured by Katz ADL/ Lawton IADL Hospital discharge (baseline), 3 months post-discharge
Secondary Change in quality of life from baseline to 3 months to 6 months after hospital discharge. Measured by Sociodemographic Survey 3 months post-discharge, 6 months post-hospital discharge
Secondary Change in quality of life from baseline to 3 months to 6 months after hospital discharge. Measured by Employment Survey 3 months post-discharge, 6 months post-hospital discharge
Secondary Change in quality of life from baseline to 3 months to 6 months after hospital discharge. Measured by EQ-5D-5L 3 months post-discharge, 6 months post-hospital discharge
Secondary Change in quality of life from baseline to 3 months to 6 months after hospital discharge. Measured by Katz ADL/ Lawton IADL 3 months post-discharge, 6 months post-hospital discharge
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3